Upgrades Hold Buy X

NVO Novo Nordisk A/S

Kepler

Downgrades Buy Hold X

NVO Novo Nordisk A/S

Stifel

Initiated Equal-Weight X

NVO Novo Nordisk A/S

Morgan Stanley

Upgrades Underperform Mkt Perform X

NVO Novo Nordisk A/S

Bernstein

Initiated Buy X

NVO Novo Nordisk A/S

Goldman

$156

Initiated Outperform X

NVO Novo Nordisk A/S

BMO Capital Markets

$163

Initiated Overweight X

NVO Novo Nordisk A/S

Morgan Stanley

$120

Resumed Neutral X

NVO Novo Nordisk A/S

UBS

Initiated Overweight X

NVO Novo Nordisk A/S

Cantor Fitzgerald

$120

Initiated Buy X

NVO Novo Nordisk A/S

Argus

$110

Initiated Buy X

NVO Novo Nordisk A/S

HSBC Securities

Upgrades Eq-Weight Overweight X

NVO Novo Nordisk A/S

Morgan Stanley

Downgrades Neutral Sell X

NVO Novo Nordisk A/S

UBS

Upgrades Underperform Neutral X

NVO Novo Nordisk A/S

Exane BNP Paribas

Upgrades Neutral Overweight X

NVO Novo Nordisk A/S

JP Morgan

Upgrades Neutral Buy X

NVO Novo Nordisk A/S

Guggenheim

Upgrades Mkt Perform Outperform X

NVO Novo Nordisk A/S

Cowen

$130

Upgrades Underweight Eq-Weight X

NVO Novo Nordisk A/S

Morgan Stanley

Upgrades Hold Buy X

NVO Novo Nordisk A/S

Deutsche Bank

Downgrades Hold Sell X

NVO Novo Nordisk A/S

Liberum

Downgrades Overweight Neutral X

NVO Novo Nordisk A/S

JP Morgan

Downgrades Outperform Neutral X

NVO Novo Nordisk A/S

Credit Suisse

Initiated Buy X

NVO Novo Nordisk A/S

Deutsche Bank

Downgrades Buy Hold X

NVO Novo Nordisk A/S

Deutsche Bank

Upgrades Underweight Eq Weight X

NVO Novo Nordisk A/S

Barclays

Upgrades Neutral Outperform X

NVO Novo Nordisk A/S

Credit Suisse

Initiated Outperform X

NVO Novo Nordisk A/S

Exane BNP Paribas

Resumed Hold X

NVO Novo Nordisk A/S

Jefferies

Initiated Buy X

NVO Novo Nordisk A/S

Guggenheim

NVO  Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.